The anti-PD-L1 antibody Atezolizumab was analysed in IMbrave150, a phase III trial, in combination with the anti-VEGF antibody Bevacizumab vs. Sorafenib in patients with unresectable HCC (1–12). Here, CD274 is linked to hepatocellular carcinoma.